Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
51 results about "Viral neuraminidase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Viral neuraminidase is a type of neuraminidase found on the surface of influenza viruses that enables the virus to be released from the host cell. Neuraminidases are enzymes that cleave sialic acid groups from glycoproteins and are required for influenza virus replication.
Multivalent neuraminidase inhibitor conjugates
InactiveUS7205333B2High binding affinityReduce capacityBiocideMicrobiological testing/measurementReactive siteActive site
The invention relates to a multimeric compound or a pharmaceutically acceptable salt or derivative thereof which comprises three or more neuraminidase-binding groups attached to a spacer or linking group, in which the neuraminidase-binding group is a compound which binds to the active site of influenza virus neuraminidase, but is not cleaved by the neuraminidase. The invention also relates to processes for the preparation of the multimeric compound defined above, pharmaceutical compositions containing them or methods for the treatment and / or prophylaxis of a viral infection involving them.
Owner:BIOTA SCI MANAGEMENT PTI LTD
Fucosan sulphate, preparation method thereof, and application of fucosan sulphate in preparing anti-influenza virus medicine
The invention belongs to the field of marine medicines, and relates to a fucosan sulphate, a preparation method thereof and application of the fucosan sulphate in preparing an anti-influenza virus medicine. Polysaccharide with a main chain taking alpha-1,2-D-mannose and beta-1,4-D-glucuronic acid as repetitive units, and with a branched chain of alpha-1,3-L-fucosan sulphate is obtained by virtue of hot-water extraction, calcium chloride precipitation and DEAE-Cellulose chromatographic column purification. The fucosan sulphate prepared by the invention is high in inhibition effect on the influenza virus neuraminidase activities of A H1N1, H5N1 and H3N2, and obvious in protection effect on the dog kidney epithelial cells infected by A H1N1. The fucosan sulphate provided by the invention has the advantages of being rich in raw material source, simple in preparation process, easy to industrialize, high in product water solubility, high in stability, free from toxic and side effects, and the like, and has the prospect of being developed to the anti-influenza virus medicine.
Owner:威海人生药业有限公司
Medical application of N-{5-(1,2,4-triazole-1-yl) thiazole-2-yl} fatty acid amide
InactiveCN103705511AGood anti-influenza virus neuraminidase activityOrganic active ingredientsAntiviralsThiazoleVirus
The invention relates to application of N-{5-(1,2,4-triazole-1-yl) thiazole-2-yl} fatty acid amide in preparing an influenza virus neuraminidase inhibitor. The N-{5-(1,2,4-triazole-1-yl) thiazole-2-yl} fatty acid amide has the chemical structural formula shown as I, wherein in the formula I, R is selected from C1 to C2 alkyls, C3 to C4 straight chains or branched alkyls; R1 is selected from C1 to C2 alkyls, C3 to C11 straight chains or branched alkyls, C12 to C17 straight chains or branched alkyls, vinyls, allyls or C4 to C17 alkyls containing dual keys or three keys.
Owner:CHANGSHA UNIVERSITY OF SCIENCE AND TECHNOLOGY
3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof
InactiveCN103755697AHas anti-influenza drug neuraminidase activityOrganic chemistryAntiviralsThiazoleHydrogen
The invention relates to 3-[[2-(benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as shown in chemical structural formulas I and II or a salt thereof. In the chemical structural formulas, R, X<1> and X<2> are selected from hydrogen, deuterium, C1-C2 alkyl, C3-C4 linear-chain alkyl or branched-chain alkyl; X<3> is selected from hydroxyl, methoxyl and ethyoxyl; is selected from hydrogen, deuterium, C1-C2 alkyl, fluorine, fluorine or bromine; X4 and X6 are selected from hydrogen, deuterium, C1-C2 alkyl, fluorine, fluorine, bromine or nitryl; X5 and X7 are selected from hydrogen, deuterium and C1-C2 alkyl. The invention also provides an application of the 3-[[2-(benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone in preparation of an influenza virus neuraminidase inhibitor.
![3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof](https://images-eureka.patsnap.com/patent_img/1ec64ec5-fc1c-433f-bd19-00bb4ff43c61/BDA0000456427430000021.PNG "3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof")
![3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof](https://images-eureka.patsnap.com/patent_img/1ec64ec5-fc1c-433f-bd19-00bb4ff43c61/BDA0000456427430000022.PNG "3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof")
![3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof](https://images-eureka.patsnap.com/patent_img/1ec64ec5-fc1c-433f-bd19-00bb4ff43c61/BDA0000456427430000023.PNG "3-[[2-(2-benzylamino) thiazole-5-yl]-methyl] quinolone-2(1H)-ketone as well as preparation and application thereof")
Owner:HUNAN UNIV
Cyclohexene compound having influenza virus neuraminidase inhibition activity, preparation method and application
InactiveCN102964267AHas neuraminidase inhibitory activityOvercoming drug resistanceCarbamic acid derivatives preparationCarboxylic acid nitrile preparationCyclohexeneEnantiomer
The invention provides a compound expressed by a general formula I, or its pharmaceutically acceptable salt, and an analyzed enantiomer and a purified diastereomer, wherein R<1>is H or C1-12 alkyl groups; R<2> is H, -C(O)R<1a>, -C(O)OR<1a> or -S(O)2R<1b>, wherein R<1a> is H or C1-6 alkyl groups, R<1b> is selected from H or C1-6 alkyl groups halogenated hydrocarbon, phenyl or aryl group; R<3> is selected from C1-4 alkyl groups substituted amino, halogen, hydroxyl, sulfydryl, guanidyl, nitryl or cyano group; and R<4> is -(CH2)nCO2H, -(CH2)nP(O)(OH)2, -(CH2)nCO2R<1a> and -(CH2)nP(O)(OR<1a>)2, wherein R<1a> is H or C1-6 alkyl groups, n is an integer between 0 and 4, or a salt of the above groups. The invention also provides a preparation method of the cyclohexene compound expressed by the general formula I, and an application of the cyclohexene compound taken as an influenza virus neuraminidase inhibitor for preparing the medicines to prevent or treat the influenza diseases.
Owner:SUN YAT SEN UNIV
Cyclohexene derivative or its pharmaceutically acceptable salt and application thereof
ActiveCN103224464AStrong inhibitory activityHigh activityOrganic chemistryAntiviralsCyclohexeneOseltamivir resistant
Belonging to the field of pharmaceutical chemistry, the invention discloses a cyclohexene derivative shown as formula I or its pharmaceutically acceptable salt. The cyclohexene derivative or its pharmaceutically acceptable salt has good inhibitory activity on influenza virus neuraminidase, and especially has high activity on the neuraminidase of oseltamivir resistant influenza virus strains.
Owner:GUANGZHOU HENOVCOM BIOSCI CO LTD
Rapid detection method of influenza virus neuraminidase antibody
ActiveCN102023212AExtensive testingShort reaction timeFermentationVector-based foreign material introductionAgglutinationViral neuraminidase
The invention belongs to the technical field of biology and particularly relates to a rapid detection method of an influenza virus neuraminidase antibody. The detection method comprises the following steps of: coning the influenza virus neuraminidase gene and then transfecting eukaryotic cells so that influenza virus neuraminidase protein is in recombination expression on the surface of eukaryotic cells, combining with the influenza virus neuraminidase antibody in a sample to be detected, performing agglutination reaction and judging whether the influenza virus neuraminidase antibody exists in the sample to be detected according to whether the agglutination reaction happens or not. The method is simple, rapid, stable and highly sensitive, and has wide application value.
Owner:SHANTOU UNIV MEDICAL COLLEGE
Use of 4-alkyl-6-aryl-5-acetyl-1,3-thiazine for preparing neuraminidase inhibitor
The invention discloses use of 4-alkyl-6-aryl-5-acetyl-1,3-thiazine represented by a chemical structural formula I and 4-alkyl-6-aryl-5-acetyl-2-amino-1,3-thiazine salts, or 4-alkyl-6-aryl-5-acetyl-2-amido-1,3-thiazine represented by a chemical structural formula II and 4-alkyl-6-aryl-5-acetyl-2-amido-1,3-thiazine salts for preparing a neuraminidase inhibitor of influenza viruses.
Owner:HUNAN UNIV
Pan-antiviral peptides
ActiveUS7259237B1Reduction of neuraminidase activity peakSsRNA viruses negative-sensePeptide/protein ingredientsDisulfide bondViral neuraminidase
Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disulfide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.
Owner:HOWFISH LLC
Zanamivir phosphonate congeners with Anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
ActiveUS20130225532A1Reduce the binding effectBiocideOrganic active ingredientsCompetitive bindingWild type
Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non-oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided.
Owner:ACAD SINIC
Influenza virus H1N1 subtype neuraminidase as well as gene, inhibitor screening model and application thereof
InactiveCN102586295ABiologically activeHigh secretion and expression efficiencyFungiHydrolasesPichia pastorisHigh-Throughput Screening Methods
The invention provides influenza A-type influenza virus neuraminidase (NA), a gene and a preparation method thereof as well as a construction method of a screening model of an influenza virus neuraminidase inhibitor. Particularly, influenza A-type influenza virus H1N1 subtype neuraminidase is secretly expressed by pichia pastoris to obtain the neuraminidase with biological activity, and particularly, the truncated neuraminidases of 82 amino acids at N end of an NA full-length sequence is removed, so that an operation process of the NA prepared by totivirus, which is complicated, consumes time and has a safety problem, is avoided. According to the invention, the A-type influenza virus H1N1 subtype neuraminidase inhibitor screening model is also constructed by utilizing the neuraminidase; and the influenza virus H1N1 subtype neuraminidase has the advantages of definite mechanism of drug action, less material consumption, quick screening speed, high sensitivity, easy realization of high throughput screening and the like.
Owner:SHANGHAI INST OF PHARMA IND
Enhanced Anti-influenza agents conjugated with Anti-inflammatory activity
Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
Owner:ACAD SINIC
Baicalin injection with anti-influenza virus effect
InactiveCN103720650ASmall side effectsRelieves symptoms of infectionOrganic active ingredientsPharmaceutical delivery mechanismSide effectIn vivo
The invention relates to a baicalin injection with anti-influenza virus effect, which is prepared from baicalin weighed according to required volume and set concentration, 0.6g of sodium dihydrogen phosphate, 2.16g of disodium hydrogen phosphate and 100ml of injection water through high-temperature high-pressure sterilization, wherein the pH value of sodium hydroxide is regulated to 7.0. The medicine has a remarkable advantages of in-vivo and in-vitro anti-influenza virus activity, high bioavailability, small side effect and adverse response and the like, has the effect of inhibiting neuraminidase activity to stop virus release, has unique advantages and wide development prospect in the field of preventing and treating influenza virus.
Owner:CHINA PHARM UNIV
MASA (multi-analyte suspension array) detection kit for influenza virus H5N1 subtype and H7N9 subtype
ActiveCN104388599AStrong specificityHigh sensitivityMicrobiological testing/measurementHemagglutininMulti analyte
The invention relates to the field of biological medicines, particularly to an MASA (multi-analyte suspension array) detection kit for influenza virus H5N1 and H7N9 subtypes, and provides a primer pair and a probe for detecting influenza virus surface hemagglutinin antigen H5 and H7 subtypes, a primer pair and a probe for detecting influenza virus neuraminidase antigen N1 and N9 subtypes as well as a kit comprising the primer pairs and the probes and a usage method of the kit. The kit is good in sensitivity, accuracy and specificity and simple, convenient and quick to use, and detection of to-be-detected samples can be finished within four hours. Tests prove that no false positive result exists when the kit is used for detecting negative samples; the detection rate of 100% is realized when the kit is used for detecting samples containing H7N9 subtype viruses and H5N1 subtype viruses only; the H7N9 and H5N1 subtype viruses contained in samples can be completely detected when the kit is used for detecting the samples containing both the H5N1 subtype viruses and the H7N9 subtype viruses. Besides, the kit can be used for effectively detecting to-be-detected samples containing more than 10 copies.
Owner:INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
Owner:ACAD SINIC
Pan-antiviral peptides
ActiveUS8940867B2SsRNA viruses negative-sensePeptide/protein ingredientsDisulfide bondViral neuraminidase
Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disuifide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.
Owner:HOWFISH LLC
Application of AIV (avian influenza virus) H7N9 NA (neuraminidase) inhibitor
The invention belongs to the technical field of antiviral drugs in natural active matters, and particularly relates to an application of baicalin which has the activity of inhibiting AIV (avian influenza virus) H7N9 NA (neuraminidase). The baicalin has the activity of inhibiting the AIV H7N9 NA. Researches show that the baicalin has the obvious activity of inhibiting wild type and oseltamivir-resistant AIV H7N9 NA and has the application of preparation of drugs for resisting AIVs. The AIV NA is the wild type and oseltamivir-resistant AIV A / Anhui / 1 / 2013 (H7N9) NA recombined and expressed in CHO-K1 cells. Research results show that the baicalin has the application of preparation of the drugs for resisting the AIV H7N9.
Owner:CHINA PHARM UNIV
Compounds useful for inhibiting paramyxovirus neuraminidase
Certain cyclic compounds are presented as well as their use for inhibiting paramyxovirus neuraminidase. The compounds are represented by the following formulas:
Owner:BIOCRYST PHARM INC
Feruloyl amide derivative as well as medical application and crystal structure thereof
ActiveCN112209922AOrganic active ingredientsOrganic chemistry methodsAcyl groupPharmaceutical medicine
The invention relates to a feruloyl amide derivative as shown in a formula I and pharmaceutically acceptable salt thereof, a pharmaceutical composition and a crystal structure thereof, and applicationof the feruloyl amide derivative and the pharmaceutically acceptable salt thereof in preparation of an influenza virus neuraminidase inhibitor. In the formula I, R and R1 are selected from hydrogen,C1-C2 alkyl, C3-C4 linear alkyl or C3-C4 branched alkyl; R2 is selected from hydrogen, a C1-C2 alkyl group, a C3-C4 linear alkyl group or a C3-C4 branched alkyl group, carboxymethyl and a C1-C4 alkoxycarbonyl methyl group; and R3 is selected from hydrogen, C1-C2 alkyl, C3-C4 straight-chain alkyl or C3-C4 branched-chain alkyl, nitro, alkoxy carbonyl, alkanoyl, 1-imidazolyl, 1, 2, 4-triazole-1-yl or 1-(methoxy imino)alkyl.
Owner:湖南先施制药有限公司
N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof
The invention relates to applications of N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]benzamide represented by chemical structural formula I in preparing influenza neuraminidase inhibitors. According to the chemical structural formula I, R is selected from C1-C2 alkyl, and C3-C4 linear or branched alkyl; R1 and R5 are selected from hydrogen, deuterium, methyl, ethyl, hydroxyl, methoxyl, ethyoxyl, fluorine, chlorine, bromine, nitryl, or trifluoromethyl; R2 and R4 are selected from hydrogen, deuterium, methyl, ethyl, hydroxyl, methoxyl, ethyoxyl, fluorine, chlorine, bromine, nitryl, trifluoromethyl, amino, or acetamido; and R3 is selected from hydrogen, deuterium, methyl, ethyl, hydroxyl, methoxyl, ethyoxyl, fluorine, chlorine, bromine, nitryl, trifluoromethyl, cyanogroup, amino, or acetamido.
![N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof](https://images-eureka.patsnap.com/patent_img/747eb220-8a6d-4331-9d88-57994c72d1d3/BDA0000454795420000021.PNG "N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof")
![N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof](https://images-eureka.patsnap.com/patent_img/747eb220-8a6d-4331-9d88-57994c72d1d3/BDA0000454795420000022.PNG "N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof")
![N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof](https://images-eureka.patsnap.com/patent_img/747eb220-8a6d-4331-9d88-57994c72d1d3/BDA0000454795420000031.PNG "N-[5-(1,2,4-triazole-1-yl)thiazole-2-yl]aromatic amide, and pharmaceutical applications thereof")
Owner:HUNAN UNIV
Reagents and methods for detecting influenza virus proteins
ActiveUS20120141519A1SsRNA viruses negative-senseViral antigen ingredientsSequence analysisConserved sequence
Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
Owner:LI XUGUANG +2
4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof
InactiveUS20120101157A1ActivityEasy to modifyBiocideUrea derivatives preparationAnti influenza drugViral neuraminidase
Disclosed are 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and manufactures thereof. The 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives are presented by formula (I):wherein R1 group is H, CH3, or C2H5; R2 group is H, or Br; R3 group is CH3, or C3H7; and R4 group is H, or C(═NH)—NH2. 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives provided here were non-toxic to MDCK cells, particularly compounds 6a, 6b, 6c, 6e, 6f, 7a, 7b and 8 had better anti-H1N1 activity. In the future, these compounds can be used to focus on viral neuraminidases as targets to develop effective anti-influenza drugs.
Owner:NAT DEFENSE MEDICAL CENT
Multiplex fluorescent RT-PCR kit for detection of H7N9 classic strains and highly pathogenic variant strains
ActiveCN107502680BEfficient detection toolOvercoming problems such as mutual interferenceMicrobiological testing/measurementMicroorganism based processesHemagglutininMultiplex
Owner:ZHENGZHOU ZHONGDAO BIOTECHNOLOGY CO LTD +1
Application of calcein and oseltamivir in drug for preventing and treating H7N9 influenza
ActiveCN106074498AInhibitory activityInhibition of reproductionOrganic active ingredientsAntiviralsMedicineWild type
Provided is application of calcein and oseltamivir in a drug for preventing and treating H7N9 influenza. According to the technical scheme, the method comprises the steps that an H7N9 wild-type or mutant-type influenza virus neuraminidase solution and a calcein and oseltamivir mixed solution are subjected to incubation for 30 min, and a substrate is added for detection; it is shown through experimental results that combined usage of the two drugs has inhibiting effects on activity of both H7N9 wild-type and mutant-type influenza virus neuraminidase, the anti-influenza effect of combined usage of calcein and oseltamivir at a cellular level is detected, and it is found that combined usage of calcein and oseltamivir can have a treatment effect on cells infected with H7N9 wild-type and mutant-type influenza viruses; finally, the influence of combined usage of calcein and oseltamivir on a mouse influenza model is detected, reduction of weight of a mouse with influenza can be obviously relieved, the mouse gradually restores to the healthy level, and the lung index of the mouse with the influenza can be significantly decreased.
Owner:JILIN UNIV
Cyclohexene compound having influenza virus neuraminidase inhibition activity, preparation method and application
InactiveCN102964267BHas neuraminidase inhibitory activityOvercoming drug resistanceCarbamic acid derivatives preparationCarboxylic acid nitrile preparationCyclohexeneEnantiomer
The invention provides a compound expressed by a general formula I, or its pharmaceutically acceptable salt, and an analyzed enantiomer and a purified diastereomer, wherein R<1>is H or C1-12 alkyl groups; R<2> is H, -C(O)R<1a>, -C(O)OR<1a> or -S(O)2R<1b>, wherein R<1a> is H or C1-6 alkyl groups, R<1b> is selected from H or C1-6 alkyl groups halogenated hydrocarbon, phenyl or aryl group; R<3> is selected from C1-4 alkyl groups substituted amino, halogen, hydroxyl, sulfydryl, guanidyl, nitryl or cyano group; and R<4> is -(CH2)nCO2H, -(CH2)nP(O)(OH)2, -(CH2)nCO2R<1a> and -(CH2)nP(O)(OR<1a>)2, wherein R<1a> is H or C1-6 alkyl groups, n is an integer between 0 and 4, or a salt of the above groups. The invention also provides a preparation method of the cyclohexene compound expressed by the general formula I, and an application of the cyclohexene compound taken as an influenza virus neuraminidase inhibitor for preparing the medicines to prevent or treat the influenza diseases.
Owner:SUN YAT SEN UNIV
Composition comprising a peptide and an inhibitor of viral neuraminidase
The invention relates to a composition comprising a peptide and an inhibitor of viral neuraminidase. Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.
Owner:阿佩普蒂科研究和开发有限责任公司
2-(2-Benzylhydrazonyl)-5-(1,2,4-triazole-1-yl)thiazole and its preparation and application
The invention relates to 2-(2-benzylidene hydrazino)-5-(1,2,4-triazole-1-yl)thiazole represented by chemical structural formula I, or salts thereof. According to the chemical structural formula I, R is selected from hydrogen, deuterium, C1-C2 alkyl, and C3-C4 linear alkyl or branched alkyl; and X1-X5 are selected from hydrogen, deuterium, C1-C2 alkyl, hydroxyl, methoxyl, ethyoxyl, fluorine, chlorine, bromine, and nitryl. The invention also discloses applications of 2-(2-benzylidene hydrazino)-5-(1,2,4-triazole-1-yl)thiazole in preparing influenza neuraminidase inhibitors.
Owner:HUNAN UNIV
Rapid detection method of influenza virus neuraminidase antibody
ActiveCN102023212BExtensive testingShort reaction timeFermentationVector-based foreign material introductionAgglutinationViral neuraminidase
The invention belongs to the technical field of biology and particularly relates to a rapid detection method of an influenza virus neuraminidase antibody. The detection method comprises the following steps of: coning the influenza virus neuraminidase gene and then transfecting eukaryotic cells so that influenza virus neuraminidase protein is in recombination expression on the surface of eukaryotic cells, combining with the influenza virus neuraminidase antibody in a sample to be detected, performing agglutination reaction and judging whether the influenza virus neuraminidase antibody exists in the sample to be detected according to whether the agglutination reaction happens or not. The method is simple, rapid, stable and highly sensitive, and has wide application value.
Owner:SHANTOU UNIV MEDICAL COLLEGE
Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase
ActiveUS20200299331A1Good treatment effectSimple compositionOrganic active ingredientsPeptide/protein ingredientsHexamerinsReceptor
Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.
Owner:APEPTICO FORSCHUNG & ENTWICKLUNG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com